FibroBiologics, Inc. Common Stock (FBLG) Stock Price

FBLGStock
$0.97−88.16%52W
Market Cap$6.88M
P/E—
PEG Ratio—
Div yield—
Beta1.85

FBLG Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-41.04%
Price vs S&P 500 (4W)-27.28%
VGM Score50.16

FBLG Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.93-$0.66+29.03%(+$0.27)
Q1 2026-$1.35-$1.33+1.85%(+$0.02)
Q4 2025-$2.00-$0.60+70.00%(+$1.40)
Q3 2025-$2.30-$2.60-13.04%(-$0.30)
Q2 2025-$2.25-$2.40-6.67%(-$0.15)

FBLG Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.00
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
FBLGFibroBiologics, Inc. Common Stock
——C————$0.97
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About FibroBiologics, Inc. Common Stock

FibroBiologics Inc is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, and psoriasis. The company's pipeline comprises four candidates: CYWC628, CYPS317, CYMS101, and CybroCell, with additional exploration in oncology and age-related conditions, including novel approaches to reverse thymic involution.